157730-78-4

Basic information

• Product Name: 9-benzyloxy-1-nonanal
• Synonyms: 9-benzyloxy-1-nonanal
• CAS NO: 157730-78-4
• Molecular Weight: 248.365
• Mol File: 157730-78-4.mol
• Article Data: 17

Chemical Properties

• CAS DataBase Reference: 9-benzyloxy-1-nonanal(CAS DataBase Reference)
• NIST Chemistry Reference: 9-benzyloxy-1-nonanal(157730-78-4)
• EPA Substance Registry System: 9-benzyloxy-1-nonanal(157730-78-4)

Safety Data

• Hazardous Substances Data: 157730-78-4(Hazardous Substances Data)

Upstream product

• 199382-23-5 ((non-8-en-1-yloxy)methyl)benzene 
• 1118635-06-5 (E)-9-(benzyloxy)non-2-enoic acid 
• 201230-82-2 carbon monoxide 
• 100-39-0 benzyl bromide 
• 3937-56-2 1,9-Nonanediol 
• 104876-10-0 9-(phenylmethoxy)nonan-1-ol 

Downstream Products

• 221217-34-1 (2S,3R,4S)-2-Hydroxymethyl-4-((11S,12S)-11-hydroxy-12-methyl-tetradecyl)-1-(toluene-4-sulfonyl)-azetidin-3-ol 
• 77285-25-7 (Z)-2-(heptadec-10-en-1-yl)-6-methoxybenzene-1,4-diol 
• 56495-82-0 (Z)-2-(heptadec-10-en-1-yl)-6-methoxycyclohexa-2,5-diene-1,4-dione 
• 144078-13-7 3-Methoxy-5-<(Z)-heptadec-10'-enyl>phenol 
• 137786-97-1 10-(3,5-dimethoxyphenyl)decanal 
• 152430-95-0 10-(3,5-Dimethoxy-phenyl)-decan-1-ol 
• 104876-10-0 9-(phenylmethoxy)nonan-1-ol 

Relevant articles and documents

Stereoselective total synthesis of penaresidin A starting from d-galactal

A stereoselective total synthesis of penaresidin A has been accomplished involving Sharpless asymmetric epoxidation, regioselective ring-opening of epoxide, azetidine formation via SN2 reaction, Jung's protocol, and Julia-Kocienski olefination.

LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS

The disclosure features amino lipids and compositions involving the same. Nanoparticle compositions include an amino lipid as well as additional lipids such as phospholipids, structural lipids, PEG lipids, or a combination thereof. Nanoparticle compositions further including therapeutic and/or prophylactic agents such as RNA are useful in the delivery of therapeutic and/or prophylactic agents to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.